Oral Drug Cut Hereditary Angioedema Attacks by 83%
A new oral treatment significantly reduced monthly attacks for patients living with hereditary angioedema.
Updated on Sept. 22, 2026 in Allergies
Live Poll
Do you trust that new oral medications for chronic conditions are as effective as traditional injections?
In the global phase 3 CHAPTER-3 study, a daily 40 mg oral dose of deucrictibant extended-release tablets reduced monthly hereditary angioedema (HAE) attack rates by 83% compared to placebo. The findings offer a potential future long-term prophylactic option for the 85 patients aged 12 and older evaluated in the trial.
Why it matters
Hereditary angioedema is a debilitating condition characterized by unpredictable swelling, and finding effective, long-term oral prophylaxis is a major goal for managing quality of life. This study represents a clinical effort to establish a daily treatment that can reliably lower the frequency of these attacks.
A phase 3 trial of 85 participants aged 12 or older found that 45.5% of those taking daily deucrictibant were attack-free over 24 weeks. Results showed a clear efficacy advantage over placebo, though adverse events occurred in 76.4% of treated participants versus 56.7% in the placebo group.
The players
FDA
The United States government agency responsible for regulating new drug applications and evaluating the safety and efficacy of medical therapies.
The details
Deucrictibant is designed as a long-term prophylactic therapy to be taken orally on a daily basis. The trial measured its efficacy by tracking investigator-confirmed HAE attack rates over a 24-week period. By comparing the daily 40 mg dose against a placebo, researchers evaluated the medication's ability to prevent the recurring swelling episodes associated with the condition.
Timeline
The clinical study treatment period lasted for 24 weeks.
A new drug application for long-term prophylaxis is planned for the first half of 2027.
The FDA target date for the separate on-demand treatment application is April 23, 2027.
Health Landscape
The CHAPTER-3 clinical study provides pivotal data for the development of oral daily prophylactics for HAE. This research advances the field beyond existing standards by testing an extended-release formula aimed at reducing the total burden of monthly attacks.
Patients currently managing hereditary angioedema should note that this oral treatment is currently under development with a future filing planned for 2027. If you are interested in how these emerging prophylactic options might fit into your treatment plan, discuss the latest clinical findings with your doctor.
The takeaway
This study highlights an 83% reduction in HAE attacks, suggesting that oral daily therapies could substantially change long-term disease management. Patients should continue to monitor their current symptom frequency and consult with an immunologist about new developments in prophylactic care.
Further reading
For more information on the current management of hypersensitivity and immune conditions, visit the Allergies section.
Source note: This article includes information reported by Healio.
Live Poll
Do you trust that new oral medications for chronic conditions are as effective as traditional injections?
